IDEXX Laboratories, Inc. IDXX
Composite 56/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Quality ranks 84/100 — a strong point in its favour. Growth ranks 68/100 — a moderate point in its favour. Balance-sheet strength ranks 67/100 — a moderate point in its favour.
Valuation ranks 24/100 — a strong mark against it. Momentum ranks 29/100 — a moderate mark against it.
What the company does IDEXX Laboratories designs and sells diagnostic instruments and tests for veterinary, livestock, poultry, dairy, and water-testing markets. Its portfolio spans point-of-care analyzers, reference lab services, and AI-driven cancer diagnostics.
Key financials IDEXX posts exceptional profitability: ROE 74.2%, ROA 27.1%, ROCE 67.9%, gross margin 62.4%, operating margin 35.0%, net margin 25.0%. Revenue grew 9.7% and EPS 17.6% year-over-year. Balance sheet metrics are strong: debt/equity 0.68, interest coverage 37.44, current ratio 1.17.
Stock health Momentum is weak: -17.01% over 12 months, -28.44% from the 52-week high, RSI(14) 43.00. The stock underperformed peers despite robust fundamentals, with 6-month and 3-month returns of -10.73% and 3.40%.
Price vs fair value IDEXX trades at a discount of 26.90% versus the analyst mean target of 698.92. - Recent AI and cancer-test initiatives highlight long-term growth potential (MarketBeat 2026-08-14). - Strong Q2 2026 results and a new cardiac test may support the narrative (Simply Wall St. 2026-08-13). - Q2 2026 earnings call transcript underscores execution and pipeline strength (Motley Fool 2026-08-11).
Looking forward Analysts expect continued margin stability and mid-single-digit revenue growth, but valuation remains rich (forward P/E 40.32). Execution on AI diagnostics and global expansion will be key catalysts to justify the premium.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.